RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MORSCHHAUSER F
Collezione AOU Città della Salute di Torino

Items : 6

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bertoni F; Cavalli F; Landi F; Spina M; Re F; Pietrantuono G; Merli M; Houot R; Liberati AM; Haioun C; Devizzi L; Cartron G; Casasnovas RO; Angrilli F; Occhini U; Pulsoni A; Celli M; Califano C; Capochiani E; Cabras MG; Zanni M; Tilly H; Tessoulin B; Conconi A; Palombi F; Cavallo F; Morschhauser F; Gressin R; Marino D; et alii...

Safety and efficacy of polatuzumab vedotin?+?obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study. in American journal of hematology / Am J Hematol. 2022 Jan 1;97(1):E24-E27. doi: 10.1002/ajh.26400. Epub 2021 Nov 30.

2022
AOU Città della Salute di Torino

Morschhauser F; Hirata J; Ramies D; Cheng J; Diefenbach C; Chiappella A; Essell J; Brunvand M; Chen AI; Phillips T; Flinn IW;

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

2017
AOU Città della Salute di Torino

Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL;

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29.

2017
AOU Città della Salute di Torino

Zucca E; Conconi A; Martinelli G; Bouabdallah R; Tucci A; Vitolo U; Martelli M; Pettengell R; Salles G; Sebban C; Guillermo AL; Pinotti G; Devizzi L; Morschhauser F; Tilly H; Torri V; Hohaus S; Ferreri AJM; Zachée P; Bosly A; Haioun C; Stelitano C; Bellei M; Ponzoni M; Moreau A; Jack A; Campo E; Mazzucchelli L; Cavalli F; et alii...

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.

2017
AOU Città della Salute di Torino

Sargent DJ; Salles G; Zucca E; Morschhauser F; Ladetto M; Hoster E; Fowler NH; Valente N; Fu T; De Bedout S; Nielsen T; Ghielmini M; Gyan E; Peterson BA; Vitolo U; Hochster H; Kimby E; Hagenbeek A; Herold M; Marcus R; Hiddemann W; Flowers CR; Shi Q;

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

2016
AOU Città della Salute di Torino

Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C;